Phage therapy
AssigneePherecydes Pharma
InventorsFLAVIE POUILLOT, HELENE BLOIS
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims14
An antibacterial composition comprising at least one bacteriophage having lytic activity against a Pseudomonas aeruginosa (P. aeruginosa) strain, said at least one bacteriophage selected from the bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 7 or a sequence having at least 90% identity thereto.
2-4. (canceled)
(canceled)
16-17. (canceled)
Dependencies are inferred from the claim text.